AUTOANTIGENS, AUTOANTIBODIES, AUTOIMMUNITY

Edited by: K. Conrad (Dresden, Germany)
Vol. 9 – 2013
Infection, Tumors and Autoimmunity

Report on the 11th Dresden Symposium on Autoantibodies held in Dresden on September 1–4, 2013

AUTOANTIGENS, AUTOANTIBODIES, AUTOIMMUNITY
Volume 9 – 2013
## Contents

Preface XI

### Chapter 1

**Infections, Tumors and Autoimmunity**

1. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA)
   *Carlo Perricone, Yehuda Shoenfeld*  
   Page 2

2. Possible role of infections in the pathogenesis of autoimmune liver diseases
   *Daniel S. Smyk and Dimitrios P. Bogdanos*  
   Page 5

3. GP2 – The link between innate and acquired immune system in the intestine
   *Dirk Roggenbuck, Dirk Reinhold, Dimitrios P. Bogdanos, Karsten Conrad*  
   Page 16

4. Vitamin D in infection and autoimmunity
   *E. Borella, Y. Shoenfeld*  
   Page 21

5. Clinical implications of anti-rods and rings autoantibodies in hepatitis C patients treated with interferon/ribavirin therapy
   *S. John Calise, Wendy C. Carcamo, and Edward K.L. Chan*  
   Page 25

6. The hyperferritinemic syndrome in infection and autoimmunity
   *Cristina Rosário, Yehuda Shoenfeld*  
   Page 33

7. The fate of the Ro autoantigen-associated Y RNAs in Coxsackievirus-infected cells
   *Ger J.M. Pruijn, Dirk den Braanker, Qian Feng, Frank J. van Kuppeveld*  
   Page 36

8. Autoantibodies to tumor-associated antigens (TAAs) as biomarkers in the immunodiagnosis of cancer
   *Liping Dai, Pengfei Ren, Xinxin Liu, Carlos A. Casiano, Jian-Ying Zhang*  
   Page 38

9. Immunoproteomic profiling of autoantibodies in prostate cancer: a health disparities perspective
   *Tino W. Sanchez, Anamika Basu, Saied Mirshahidi, Chen Chien-Shing, Susanne Montgomery, Colwick Wilson, Jianying Zhang, Nathan Wall and Carlos A. Casiano*  
   Page 46

10. Characterisation of novel autoantibody biomarkers in oncology and autoimmunity
    *Will Colón, Colin Wheeler, Ezam Uddin, Nicholas Workman, Pooja Agashe, Tim Vyse and Michael B. McAndrew*  
    Page 57
Chapter 2
Pathogenesis and Therapy of Autoimmune Diseases -
Novel Aspects

11 The role of neutrophil extracellular traps (NETs) in autoimmunity and generation of autoantibodies
   Elaine F. Kenny & Arturo Zychlinsky
   Page 60

12 Revisiting the cell death paradigm in systemic autoimmune diseases
   Felipe Andrade
   Page 63

13 NETs and ANCA-associated vasculitides
   Elena Csernok
   Page 69

14 Towards understanding the pathogenesis of granulomatosis with polyangiitis:
   The role of neutrophil extracellular traps
   C. Lange, E. Csernok, J.U. Holle
   Page 72

15 Aggregation of NETs: flipping the switch to resolution of inflammation
   Christine Schorn, Luis Munoz, Deborah Kienhöfer, Martin Herrmann, and Markus Hoffmann
   Page 73

16 Memory plasma cells in autoimmunity - An update
   Falk Hiepe
   Page 78

17 Protective natural autoantibodies in atherogenesis and autoimmunity
   Gregg J. Silverman and Caroline Grönwall
   Page 82

18 The interface between primary immunodeficiency and systemic lupus erythematosus
   Sandro F. Perazzio, Magda Carneiro-Sampaio, Luis E.C. Andrade
   Page 88

19 Inherited defects in nucleic acid metabolism and autoimmunity
   Stefanie Kretschmer, Nadja König, Min Ae Lee-Kirsch
   Page 94

20 Induction of autoimmunity by defects of intracellular nucleases: Mouse models for Aicardi-Goutières syndrome
   Axel Roers
   Page 98

21 Anti-AT1R and anti-ETaR autoantibodies from patients with SSc and their agonistic effects
   A. Kill, Christoph Tabeling, Anja A. Kühl, J. Günther, M.O. Becker, Harald Heidecke,
   D. Dragan, G.R. Burmester, G. Riemekasten
   Page 99

22 The use of Aptamers as a new tool for the treatment of autoantibody associated diseases
   Page 101

23 Harnessing parasitic infection to treat autoimmunity
   Miri Blank, Lachnisch Jordan, Bashi Tomer and Yehuda Shoenfeld
   Page 102
Chapter 3
Immune Reactions against Drugs

24 Clinical relevance of anti-drug antibodies
   Arno Kromminga

25 Mycophenolic acid and ribavirin induce cytoplasmic Rods and Rings (RR) structures in vivo, but only ribavirin induces anti-RR autoantibodies
   Gerson D. Keppeke, Sandro F. Perazzio, Monica S. Prado, Edward K.L. Chan, Luis Eduardo C. Andrade

26 Effects of intracellular glutamine levels on the reversible assembly of cytoplasmic rod and ring autoantigenic structures
   S. John Calise, Wendy C. Carcamo, Claire Krueger, Daniel L. Purich, and Edward K.L. Chan

Chapter 4
Autoantibodies in Systemic Autoimmune Rheumatic Diseases

4.1 Connective Tissue Diseases

27 Anti-Mup44 autoantibodies in inclusion-body myositis
   Helma Pluk, Megan Herbert, Judith Stammen-Vogelzangs, Baziel G. van Engelen, Ger J.M. Pruijn

28 Autoantibody profiling in idiopathic inflammatory myopathies: Validation of the myositis antigens Mi-2a, MDA5, NXP2 and SAE1 in a line immune assay

29 Evaluation of recombinant TIF1-γ in a line immune assay for the detection of autoantibodies in idiopathic inflammatory myopathies

30 Autoantibodies to 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)
   a novel biomarker for statin associated necrotizing myopathies
   Makoto Miyara, Olivier Benveniste, Jean-Luc Charuel, Alexander Shikhman, Olivier Boyer, Joe Philips, Lucile Musset, Michael Mahler

31 Autoantibody signatures of connective tissue disease patients identified with a bead-based assays approach
   Angelika Lueking, Petra Budde, Heike Goehler, Jessica Schwermann, Martin Gamer, Klaus Marquardt, Anna Telaar, Daniel Chamrad, Carmen Theek, Matthias Schneider, Peter Schulz-Knappe
32 Identification of novel autoantibody signatures reflecting the heterogeneity in systemic lupus erythematosus

33 What is the clinical significance of anti-Sm-antibodies in SLE patients? A comparison with anti-dsDNA-antibodies and C3
   Alexandra Richartz, Thomas Rose, Cornelia Dähnrich, Anke Rosemann, Fidan Barkhudarova, Wolfgang Schlumberger, Gerd-Rüdiger Burmester, Karl Egerer, Robert Biesen and Falk Hiepe

34 Clinical evaluation of total and high avidity anti-dsDNA antibody EIA for the diagnosis of systemic lupus erythematosus
   Pengjie Wan, Shuxia Zhou, Hua Cao, Weiping Li, Doug Scott, Joel Hardy, Tony Presitigiacomo, Jie Zheng

35 Significance of anti-C1q antibody detection in SLE patients with lupus nephritis
   Ivana Stiborová, Vlastimil Král, Stanislava Blažičková

4.2 Rheumatoid Arthritis

36 Autoantibodies in rheumatoid arthritis: predictors of disease, prognosticators of outcome and pathogenic players
   Markus Hoffmann, Karin Lundberg and Günter Steiner

37 Antibodies against carbamylated proteins in different stages of rheumatoid arthritis
   Leendert A. Trouw

38 Development and initial use of a multiplex chip-based assay for the detection of autoantibodies against citrullinated peptides in rheumatoid arthritis patients
   Johan Rönnelid, Linda Mathsson, Mats Nystrand, Lars Klareskog, Monika Hansson

39 The anti-CCP2 is the anti-citrullinated protein antibody (ACPA) with highest diagnostic value in rheumatoid arthritis
   E. Grenmyr and Y. Sommarin

40 Occurrence of anti-RA33 antibody in various types of juvenile idiopathic arthritis
   Gabor Nagy, Barbara Szasz, Diana Garan, Ibolya Szollosi, Sandor Sipka, Tamas Constantin

41 MMP-3 is a marker for disease activity in rheumatoid arthritis
   S. Reuter, T. Matthias

42 The conversion of QuantiFERON TB Gold test during biological treatment by anti-TNF preparations
   E. Zanova, D. Kozakova, I. Rybar, I. Solovic, J. Rovensky

43 Interferon-gamma and QuantiFERON-TB Gold test conversion during biological treatment
   D. Kozakova, E. Zanova, I. Rybar, I. Solovic, J. Rovensky
Chapter 5
Autoantibodies in Organ Specific Diseases

5.1
Neurological Diseases

44 New antibodies in multiple sclerosis

Bernhard Hemmer

45 Identification of coronin-1a as a novel antibody target for clinically isolated syndrome and multiple sclerosis

Myrthe Rouwette, Jean-Paul Noben, Jack Van Horssen, Bart Van Wijmeersch, Raymond Hupperts, Peter J. Jongen, Marcel M. Verbeek, Peter P. De Deyn, Piet Stinissen and Veerle Somers

46 Diagnostic and pathophysiologic relevance of autoantibodies against aquaporin-4

F. Paul, B. Wildemann, S. Jarius

47 Autoantibodies against the neuronal surface antigen DPPX: markers for an emerging neurological disease entity

Bettina Balint, Simon Nagel, Uwe Haberkorn, Christian Probst, Inga-Madeleine Blöcker, Bianca Teegen, Kristin Rentzsch, Ramona Bahtz, Lars Komorowski, Sandra Saschenbrecker, Andreas Kasrups, Martin Kuthe, Hans-Michael Meinck, Winfried Stöcker

48 Nonradioactive determination of autoantibodies against acetylcholine receptors in myasthenia gravis: A new enzyme-linked immunoassay for manual and automated processing

J. Westermann, E. Denczyk, C. Probst, L. Komorowski, W. Schlumberger

49 Generation of stable HEp-2 cell line M4 expressing human muscle-specific kinase for automatic videoscan-based immunofluorescence diagnostics of Myasthenia gravis

S. George, S. Paulick, I. Knütter, N. Röber, R. Hiemann, D. Roggenbuck, K. Conrad and J.-H. Küpper

50 Clinical validation of a novel immunofluorescence assay for the detection of anti-MuSK antibodies based on MuSK transfected HEp-2 cells

Nadja Röber, Silke Weber, Jochen Schäfer, Sandra George, Ilka Knütter, Dirk Roggenbuck, Jan-Heiner Küpper, Karsten Conrad

51 Pleural mesothelioma and anti-MA2-associated encephalitis

Adriano Jiménez-Escrígh, Silvia Medina, Ángela Carrasco

52 What should be the cut-off for VGKC complex antibodies?

Sylvie Coito, Réné-Louis Humbel

53 Multi-center validation study of DNER as the target of anti-PCA-Tr autoantibodies associated with paraneoplastic neurological syndrome

Kristin Rentzsch, Inga-Madeleine Blöcker, Bianca Teegen, Winfried Stöcker, Francesc Graus, Véronique Rogemond, Jérôme Hönnorat, Esther S.P. Huelsenboom, Peter A.E. Sillevis Smitt, Christian Probst, Lars Komorowski
54 Multi-parametric recombinant cell-based indirect immunofluorescence assay (RC-IFA) for the determination of autoantibodies associated with paraneoplastic neurological syndromes
Inga-Madeleine Blöcker, Christiane Radzimski, Mandy Unger, Linda Döring, Winfried Stöcker, Josep Dalmau, Peter Sillevi Smitt, Lars Komorowski, Christian Probst

5.2 Liver and Gastrointestinal Diseases

55 Preliminary report: Detection of antibodies against D-3-phosphoglycerate dehydrogenase (PGDH) in autoimmune liver diseases using a line immune assay

56 Can the HEp-2 cell assay replace the indirect immunofluorescence on rat cryostat section for AMA-M2 screening?
Kristin Kühnert, Uta Kießling, Teresa Trimpop, Manuela Rejzek, Andrea Thieme, Nadja Röber, Karsten Conrad

57 Prevalence of anti-nuclear antibodies in patients with primary biliary cirrhosis
Ana Kozmar, Ivan Padjen, Miroslav Mayer, Mirna Sentic, Branko Malenica

58 Evaluation of a high sensitive assay for the diagnosis of celiac disease
Lisbeth Witt, Martin Salden, Klas Sjöberg, Fritz Koning and Yngve Sommarin

59 CytoBead-assay for the simultaneous detection of celiac disease specific antibodies and IgA deficiency
Nadja Röber, Kai Grossmann, Ilka Knütter, Rico Hiemann, Mandy Sowa, Martin W. Laass, Karsten Conrad, Dirk Roggenbuck

60 Pancreatic-specific autoantibodies to glycoprotein 2 in pediatric celiac disease
Martin W. Laass, Dirk Roggenbuck, Ursula Range, Nadja Röber, Karsten Conrad

61 Comparison of two ELISAs for the detection of anti-MZGP2 antibodies as a new serological marker for Crohn`s disease
Laura M. Stinton, Gary L. Norman, Zakera Shums, Maria T. Arias-Loste, Marcos Lopez-Hoyos, Michael Mahler

5.3 Endocrine, Kidney and Skin Diseases

62 Detection of autoimmunity against the insulin- and insulin-like growth factor-1 receptor and their prevalence in humans
T. Welsink, C. Schwiebert, W.B. Minich, L. Schomburg

63 Role of autoantibodies anti zinc transporter protein (anti-ZnT8) in the diagnosis and follow-up of type I diabetes mellitus: an Italian experience
64  Serological profile of idiopathic membranous nephropathy cohort
Astrid Behnert, Beina Teng, Janina Müller-Deile, Andrej Skoberne, Mario Schiffer, Marvin J. Fritzler

65  Our experience with anti-phospholipase A2 receptor (PLA2R) indirect immunofluorescence test
I. Janatková, M. Hindoš, Z. Hrušková, B. Svobodová, V. Tesař, K. Malíčková, T. Zima

66  Evaluation of a new ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy

67  Detection of anti-phospholipase A2 receptor autoantibodies: A comparison of three different immunoassays
Astrid Behnert, Mario Schiffer, Michael Mahler, Marvin J. Fritzler

68  Anti-M-type Phospholipase A2 Receptor (PLA2r) antibodies in diagnosis and follow-up of idiopathic membranous nephropathy (IMN)

69  The antiphospholipid antibodies in psoriasis patients with metabolic syndrome and non-alcoholic fatty liver disease comorbidities
N. Virstyuk, M. Volochynovych, M. Nykyforuk

70  Development of sensitive and specific assays for serological diagnosis of anti-laminin 332 mucous membrane pemphigoid

71  Autoantibodies to Golgi complex and Ro51 protein in non-specific interstitial pneumonia (NSIP): case report and literature review
S. Andrejevic, B. Milenkovic, J. Stojsic, R. Stevic, B. Bonaci-Nikolic

Chapter 6
Methodical Aspects and Diagnostic Strategies

6.1
New Concepts and Novel Assays

72  New Concepts and Approaches to Autoantibody Testing
Laura M. Sinton, Marvin J. Fritzler

73  PR3-ANCA as a promising biomarker for the diagnosis of primary sclerosing cholangitis (PSC)
Laura M. Stinton, Chelsea Bentow, Michael Mahler, Gary L. Norman, Bertus Eksteen, Andrew L. Mason, Gilaad G. Kaplan, Bjorn Lindkvist, Angela Cheung, Harry Janssen, Marvin J. Fritzler
74 Standardization of reference material for autoantibody testing: the state of the art
Pier Luigi Meroni, Maria Orietta Borghi

75 New diagnostics in autoimmunity: a review and our experience
Boris Gilburd, Carlo Perricone, Enrica Cipriano, Nancy Agmon-Levin, Yehuda Shoenfeld

76 Evaluation of a novel sensitive and reliable Lateral Flow Assay (LFA) for the detection of anti-dsDNA antibodies Anti-dsDNA LFA
N. Offermann, M. Petschinka and M. Fooke

77 Microtiter plate-based multiparametric assay for detection of non-organ specific autoantibodies
Jana Langer, Erik Höchel, Klemens Löster, Martin Eberhardt, Nadja Röber, Karsten Conrad, Silvia Porstmann, Tomas Porstmann

78 CytoBead ANCA - a novel indirect immunofluorescence test for the simultaneous detection of anti-neutrophil cytoplasmic antibodies
Mandy Sowa, Ilka Knütter, Rico Hiemann, Kai Grossmann, Nadja Röber, Ursula Anderer, Karsten Conrad, Dirk Reinhold, Elena Csernok, Dirk Roggenbuck

79 Evaluation of ANCA by automated IFA image analysis on NOVA View
Carol E. Buchner, Cassandra C. Bryant, Rachel A. Rosenblum, Marlene Gonzalez, Gabriella Lakos

80 Development of a method for multiplex real-time analysis of enzymatic activity on a microbead-chip
Stefan Rödiger, Alexander Böhm, Jörg Nitschke, Luba Stavitskaya, Melanie Gruner, Alena V. Kundzer, Margarita V. Volkova, I. Generalov, Carsten Schmidt, Christian Schröder, Dirk Roggenbuck, Peter Schierack

6.2 Antinuclear Antibodies – Diagnostic Strategies and Novel Developments

81 CytoBead – A novel platform for antibody multiplex analyses
Rico Hiemann, Mandy Sowa, Kai Grossmann, Ilka Knütter, Juliane Scholz, Nadja Röber, Ursula Anderer, Dirk Reinhold, Peter Schierack, Karsten Conrad, Dirk Roggenbuck

82 Anti-nuclear antibodies: a long way to harmonization
Jan Damoiseaux, Nancy Agmon-Levin

83 Standardization of ANA-HEp-2 immunofluorescence pattern nomenclature
Wilson M. Cruvinel, Paulo L.C. Francescantonio, Alessandra Dellavance, Luis E.C. Andrade

84 ANA measurement by IIF in comparison to other methods in the diagnosis of connective tissue diseases
Xavier Bossuyt

85 Reading and interpretation of ANA immunofluorescence tests: results of a comparative study with six automated systems
Nicola Bizzaro, Stefan Platzgummer, Elio Tonutti, Antonio Antico, Danilo Bassetti, Danilo Villalta, Fiorenza Pesente, Francesco Cucchiaro, Marilina Tampoia, Renato Tozzoli

86 Efficient autoantibody titration using indirect immunofluorescence assays (IIFA)
Jan Martinek, Ivo Lochman, Alexandra Lochmanová, Vladimir Krauz
87 Autoimmunity diagnostic strategies (ANA, anti-dsDNA, anti-ENA) in Italian clinical laboratories
   A. Radice, L. Bianchi, S. Glionna, B. Trezzi

88 Evaluation of ANA testing results: is there a need for revision of our protocol for antibody
   specificity testing?
   Andrea Tesija Kuna, Ines Vukasovic, Nada Vrkic

89 Automation in ANA HEp-2 cells microscopy:
   can the machine substitute the human eye?
   Cristovao Pitangueira Mangueira, Eliane Aparecida Rosseto

90 HELIOS, a bright future for ANA - automated indirect immunofluorescence (IIF) assay

91 Comparability of the AESKUSLIDES ANA-HEp-2 antinuclear antibody (ANA) immunological
   test system with a commercially available system
   Torsten Matthias, Sascha Pfeiffer, Trishna Martins, Peter Trinder and Andrea Petzold

92 CytoBead ANA - a novel indirect immunofluorescence test for the simultaneous detection of anti-
   nuclear antibodies
   Juliane Scholz, Ilka Knüttner, Kai Grossmann, Rico Hiemann, Mandy Sowa, Nadja Röber, Karsten
   Conrad, Peter Schierack, Dirk Roggenbuck

93 Evaluation of a novel chemiluminescent assay (QUANTA Flash® CTD Screen Plus) for the rapid
   detection of autoantibodies in systemic autoimmune rheumatic diseases
   C. Bentow, A. Seaman, A. Swart, A. Shikhman, N. Goodman, M. Mahler

94 Quantitative results of automated indirect immunofluorescence enable value added reporting
   for antinuclear antibody testing
   Sofie Schouwers, Myriam Bonnet, Patrick Verschueren, René Westhovens,
   Daniel Blockmans, Godelieve Mariën, Xavier Bossuyt

95 Optimization of the automated HEp-2 cell assay by stepwise improvement of software algorithms
   Rico Hiemann, Nadja Röber, Dirk Roggenbuck, Karsten Conrad

96 Autoantibodies to mitotic cells
   René-Louis Humbel

97 Anti-nematin antibodies in practice
   J. Goetz, R.L. Humbel, G. Uettwiller, F. Habersetzer, M. Doffoel

98 The clinical significance of anti-DFS70 antibodies as part of ANA testing
   Michael Mahler

99 Prevalence and clinical associations of anti-DFS70 antibodies in samples with high titer of ANA
   but without detectable fine-specificity
   Michael Mahler, Sofie Schouwers, Roger Albesa, Eric Tena, Nathalie Vandeputte,
   Doreen Dillaerts, X. Bossuyt

100 LEDGF/DFS70 antibodies and DFS pattern in routine diagnostics
   Uwe Höpner, Tim Fülling, Uta Kießling, Teresa Trimpop, Manuela Rejzek, Andrea Thieme,
   Nadja Röber, Karsten Conrad
101 Longitudinal study of anti-DFS70 antibodies in 5 patients without antinuclear antibody associated autoimmune rheumatic disease

*Sofie Schouwers, Michael Mahler, Doreen Dilaerts, Nathalie Vandeputte, Xavier Bossuyt*

102 Evaluation of the first dot blot assay for the detection of anti DFS 70 antibodies as part of a 12plex ANA Profile

*Johannes Schulte-Pelkum, Eric Tena, Alain Vigneron, Nicolas Bodart, Michael Mahler*

103 Novel autoantibodies showing chromatin binding in the HEp-2 cell assay

*Angelika Lueking, Heike Goehler, Petra Rengers, Martin Gamer, Klaus Marquardt, Petra Budde, Anna Telaar, Daniel Chamrad, Carmen Theek, Karsten Conrad, and Peter Schulz-Knappe*
Preface

Autoimmunity is a complex network and spectrum of immune responses against self ranging from naturally occurring autoreactivity at one end of the spectrum which, in most cases, are harmless or even beneficial, to pathological (induced) autoimmunity that may be harmful by leading to the development of autoimmune diseases. Therefore, autoimmunity may play different roles in healthy and diseased subjects. For improvement of the diagnostics and therapeutics as well as prediction and prevention of autoimmune diseases, it is important to investigate all aspects of these very complex and multifactorial pathological processes. In this regard, infections may have protective or enhancing capabilities in the development of autoimmune diseases. Neutrophil extracellular trap (NET) formation is a novel mechanism that may be involved in autoimmune induction triggered by certain infections. Besides the role of accelerated NETosis, other novel aspects of autoimmune pathogenesis such as defects of intracellular nucleases, agonistic effects of anti-receptor antibodies, the role of protective natural antibodies, vitamin D, adjuvants, memory plasma cells and the innate immune system can be found in this volume. Another important area of autoimmunity is the relevance of tumor associated autoantibodies (TAAB). Regardless of their pathogenic role, TAAB may be important markers in the risk assessment or prediction of tumor development.

A major challenge for the improvement of immune diagnostics is the optimization and standardization of autoantibody determinations combined with standardized evaluation studies. On the backdrop of trying to understand the clinical relevance of autoantibodies in patients, the search for and description of new autoantibody specificities continues. Novel autoantibody biomarkers in tumors, idiopathic myopathies, multiple sclerosis, kidney diseases and rheumatoid arthritis will be presented along with new concepts and novel assays that may further improve the diagnostics of autoimmune and neoplastic diseases.

Hopefully, the data and informations described and discussed in this volume will stimulate novel concepts and research on autoimmune pathogenesis as well as the improvement of immune diagnostics and therapy.

The editors
Chapter 1
Infections, Tumors and Autoimmunity
Autoimmune/inflammatory syndrome induced by adjuvants (ASIA)

Carlo Perricone¹², Yehuda Shoenfeld²³

1) Reumatologia, Dipartimento di Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Italy
2) Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel
3) Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases, Sackler Faculty of Medicine, Tel-Aviv University, Israel

E-mail: shoenfel@post.tau.ac.il

Keywords
Adjuvant, aluminium, Saccharomyces cerevisiae, yeast, autoimmune/inflammatory syndrome induced by adjuvants, ASIA, autoantibodies, autoimmunity, vaccine

Abstract
The term “ASIA–Autoimmune/inflammatory Syndrome Induced by Adjuvants” [1] has been recently coined to describe an “umbrella” of clinical conditions namely siliconosis, Gulf War Syndrome (GWS), macrophage myofasciitis syndrome (MMF), sick building syndrome (SBS) and post-vaccination phenomena, which share similar signs or symptoms [2-6]. The most frequently reported symptoms include myalgia, myositis, arthralgia, incapacitating fatigue, neurological manifestations, fever, dry mouth and cognitive alterations. Moreover, really common is the presence of chronic fatigue syndrome [7], often associated with sleep disturbances or non-restful sleep. These shared symptoms suggested the presence of a common denominator which has been subsequently identified in the adjuvant. The adjuvant is defined as “any substance that acts to accelerate, prolong, or enhance antigen-specific immune response” [8]. It is an agent that may stimulate the immune system and increase the response to a vaccine, without having any specific antigenic effect in itself. This immune-mediated condition appears following a chronic stimulation of the immune system by agents with adjuvant characteristics. The prevalence of immune-mediated conditions is rising in different geographical areas and these geo-epidemiological changes may be explained by a complex of genetic and environmental factors [9, 10]. Genetic leads to a predisposition in developing an autoimmune or an auto-inflammatory syndrome but, the presence of an external or endogenous environmental factor, recently called “exposome” [11], is essential in triggering the immune response. The presence of a favorable genetic background for the development of such conditions explains why they are so rare [12], and also why physicians should be aware of the possible complications that may occur, for example post-vaccination, in specific individuals [13]. Silicone, alum, pristane and infectious component are some of the environmental factors that comprise an immune adjuvant effect. Also other oil substances, sometimes illegally injected for cosmetic purposes, may have an immune
Infections, Tumors and Autoimmunity

adjuvant effect and are reported to be possible inducer of ASIA [14]. These adjuvants seem to be able to induce autoimmunity both in animal models and in humans [15, 16]. There are several proposed mechanisms by which an adjuvant may trigger the immune system including polyclonal activation of B cells, effects on cellular immunity, immune regulatory cells and on viral induced antibodies, molecular mimicry, bystander activation, and epitope spreading. Molecular mimicry refers to the concept that host immune response, initially directed to bacterial or virus antigens, can target host molecules that share sequence homology or structural similarities with microbial epitopes [8]. Adjuvants accomplish this task by mimicking specific sets of evolutionarily conserved molecules (liposomes, LPSs, unmethylated CpG dinucleotide-containing DNA etc). On the other hand, other possible involved mechanisms which may induce autoimmunity are the polyclonal activation of B cells [17], the bystander activation which enhances cytokine production and further induces the expansion of auto-reactive T cells [18], and finally the epitope spreading by which invading antigen accelerate the local activation of antigen presenting cells and the over processing of antigen [19]. For the diagnosis of the disease criteria have been proposed and may aid in the diagnosis of ASIA syndrome [1]. These criteria were further validated by Zafrir et al. [20] who studied 93 patients who suffered a constellation of symptoms and fulfilling the proposed criteria of ASIA [20]. Despite the huge efforts invested in vaccine safety there are few observational studies and virtually no randomized clinical trials documenting the effects of existing vaccines on autoimmunity. Thus, there is the need of innovative clinical trial design and the vaccines should be designed in order to be risk-free. To conclude, the accumulation of many reports and the temporal association between the occurrence of autoimmune diseases and vaccination led some authors to hypothesize the presence of a causal link. Such a link may suggest that adjuvants serve as triggers for presentation of an overt disease or exacerbation of a non-symptomatic autoimmune condition, in certain individuals that are probably prone to develop such devastating event [21]. Perhaps, in twenty years physicians will be dueling with better characterized particles of autoimmunity, and the vaccines will be fully safe as well as effective. Still, the available data suggest that the benefits of vaccination outweigh the risks. Nonetheless, the recognition of ASIA has initiated the change to put more efforts in identifying the good, the bad and the ugly of vaccines and in particular of adjuvants as triggers of autoimmunity. Nonetheless, particular attention should be given in order to develop safer vaccines.

References

(2) Shoenfeld Y. Autoimmune (autoinflammatory) syndrome induced by adjuvants provides a diagnostic framework for enigmatic conditions. The Rheumatologist 2012;6:26-32
(12) Toubi E. ASIA – autoimmune syndrome induced by adjuvants: rare, but worth considering. IMAJ 2011:14,121-124
Possible role of infections in the pathogenesis of autoimmune liver diseases

Daniel S. Smyk¹ and Dimitrios P. Bogdanos¹,²

1) Institute of Liver Studies, Division of Transplantation Immunology and Mucosal Biology, King’s College London School of Medicine at King’s College Hospital, London, UK
2) Department of Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly, Thessaly, Greece

E-mail: dimitrios.bogdanos@kcl.ac.uk

Abstract

Autoimmune liver diseases include primary biliary cirrhosis (PBC), autoimmune hepatitis (AIH) and primary sclerosing cholangitis (PSC). Each condition has its own unique clinical and diagnostic features. AIH involves the hepatocytes whereas PBC and PSC involve the biliary epithelial cells. It is believed that a combination of genetic susceptibility and environmental triggers act in concert to induce these conditions. Infectious agents are included among the environmental causes, and have been of interest for several decades. It is believed that bacteria, viruses and parasites may induce autoimmune liver disease by mechanisms such as molecular mimicry and cross reactivity. The evidence underlying these theories varies from one organism to the next, and one disease to the other. The evidence linking infectious agents to PBC and AIH is much stronger than in PSC. In the case of PBC, bacterial causes have been heavily implicated, especially in regards to E. coli. This is in comparison to AIH, where mostly viruses have been implicated, although the evidence is not strong. The evidence linking infectious triggers and PSC is even scarcer. This chapter will discuss the current evidence in the literature surrounding the role of infections in the development of autoimmune liver disease.

1. Introduction

Autoimmune liver diseases represent a distinct group of autoimmune disorders affecting the hepatocytes in the case of autoimmune hepatitis (AIH) or the biliary epithelial cells (BEC) as for primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC). The clinical features, as well as the management, of these diseases differ significantly amongst each other.

Though the aetiologies of these diseases are poorly understood, infectious agents have been considered important for the induction of immune-mediated pathology.

This chapter discusses current evidence linking infections with autoimmune liver diseases.
2. Primary biliary cirrhosis

PBC is an autoimmune liver disease with a long asymptomatic phase characterized by the destruction of small and medium-size intrahepatic bile ducts [1]. Disease specific antimitochondrial antibodies (AMA) and/or antinuclear antibodies (ANA) are the serological hallmarks of PBC [2]. The diagnosis of PBC is based on biochemical evidence of cholestasis, the presence of detectable AMA (or PBC-specific ANA) and diagnostic histological features on liver biopsy [1].

Infectious agents linked to PBC are numerous [3,4]. An overview of these agents, in addition the mechanisms that have been investigated linking these micro-organisms with PBC, are provided in Table 1. It has become apparent that the evidence linking their involvement in the induction of PBC varies amongst pathogens. The most cited of those is *Escherichia coli* (*E. coli*) [4].

**E. coli as a PBC trigger**

Several epidemiological studies have been conducted to investigate risk factors for the development of PBC, including risks regarding infection (reviewed in [3]). These studies have been based on questionnaires addressing geographical and lifestyle factors, as well as personal and familial medical and surgical histories, including history of infection. One of the most significant infectious risk factors in PBC was found to be a history of recurrent urinary tract infections (rUTI) [4]. Recent data from British investigators demonstrated that rUTI precedes the diagnosis of PBC [5].

The potential pathophysiological mechanisms linking *E. coli* infection (and rUTI) with the development of PBC have been reviewed elsewhere [4]. Briefly, immunological data have also demonstrated B- and T-cell cross-reactive responses involving the major AMA-specific autoepitopic region, namely human PDC-E2, and its *E. coli* mimics. Gershwin’s lab in collaboration with Japanese co-workers subsequently demonstrated that *E. coli* and human PDC-E2 cross-react at the cellular level (CD4 T-cell) [6]. Our own group has provided data suggesting that mimics of the human PDC-E2 autoepitope originated from *E. coli* proteins irrelevant to PDC-E2 are also targeted by cross-reactive responses [7]. Also, some evidence linking *E. coli* infection with PBC has come from an animal model which demonstrated that recurrent UTI is capable of inducing histological features resembling those seen in PBC [4].

**Novosphingobium aromaticivorans: an unexpected trigger of PBC**

In search of microbial triggers of PBC, Gershwin’s group reported that two bacterial proteins from *N. aromaticivorans* were highly homologous to human PDC-E2 [8]. Also, patients with PBC demonstrated antibody responses against the lipoylated *Novosphingobium aromaticivorans* proteins. The investigators have found that *N. aromaticivorans* was isolated in faecal samples from patients with PBC, and obtained data demonstrating the existence of immune responses against lipoylated proteins of *N. aromaticivorans* in PBC patients and their first degree relatives [8]. Based on these data, an animal model of the human disease was developed in which infection of mice with *N. aromaticivorans* led to serological and histological evidence of PBC.

**The role of Lactobacillus delbrueckii in PBC**

Beta-galactosidase of *L. delbrueckii subsp. bulgaricus* is one of the very few lactobacilli proteins that have remarkable similarity with the core CD4, CD8 and B-cell epitope of human PDC-E2, the major AMA antigenic determinant. Experimental testing has demonstrated evidence of IgG antibodies against the homologous peptides being present in patients and controls. However, IgG3 antibodies to the lactobacillus
Infections, Tumors and Autoimmunity

mimic are highly specific for PBC [9, 10]. Also, IgG3 antibodies to the lactobacillus mimics cross-react with the human autoepitope PDC-E2, suggesting a potential involvement of this pathogen in the pathogenesis of PBC. In fact, one study has reported the case of an AMA positive female who developed PBC after being vaccinated with lactobacillus for recurrent vaginitis [9]. Also, serological testing has provided evidence of human and lactobacilli immunological cross-reactivity. We formulated a hypothesis based on the assumption that alterations in normal vaginal flora leading to bacterial vaginosis may provide the impetus for bacterial colonisation important for the pathogenesis of PBC [9, 10]. It is known that UTI is more frequently reported in females with alterations in the normal vaginal flora. This may allow for the colonisation of uropathogenic E. coli and subsequent development of cross-reactive immune responses involving lactobacilli mimics but this needs to be determined at the experimental level.

Mycobacterial-induced PBC: facts and fictions

Granulomata can be seen in liver biopsy specimens from patients with PBC, and this has led investigators to consider mycobacteria as potential causative agents of PBC [11]. Early studies reported the presence of PBC-specific AMA in patients with active pulmonary tuberculosis and leprosy and the presence of antibody reactive specifically targeting mycobacterial antigens in sera from patients with PBC. However, mycobacterial DNA has not been detected in livers from patients with PBC [11].

Nevertheless, a Spanish group reported the presence of antibodies against the 65-kDa heat shock protein (hsp65) of Mycobacterium gordonae extract in all patients with PBC [12], and our group has demonstrated that cross-recognition of M. gordonae hsp65 and human PDC-E2 was due to amino acid homologies between the human PDC-E2 mitochondrial autoepitope, and an hsp65 M. gordonae antigenic determinant [13].

Chlamydia pneumoniae as a cause of PBC

A single study has found that C. pneumoniae antigens are detectable in all the explanted liver tissues from patients with PBC but these data have not been confirmed by Gershwin’s group [14]. A serological study has shown that anti-chlamydial antibodies are present in the great majority (91%) of AMA-positive patients with PBC and just 21% AMA-negative patients with PBC. These antibodies were undetectable in the relevant pathological and normal controls. However, C. pneumoniae DNA could not be detected in liver tissues obtained from patients with PBC suggesting that chamydial infection is not directly involved in the pathogenesis of PBC.
Helicobacter pylori and PBC: current evidence

Reported data have failed to provide evidence in support of a causative link between *H. pylori* infection and development of PBC. In search of microbial mimics of the human PBC autoepitope, we identified significant amino acid similarity between the major mitochondrial autoepitopic region and *H. pylori* urease beta [15], but we were unable to provide evidence of cross-reactive immunity at the B- cell or T-cell level. We have also looked for molecular mimicry between between *H. pylori* VacA antigen and human PDC-E2, but again we reported lack of cross-reactive immunity of the homologous sequences. Early data suggesting that anti-helicobacter pylori antibodies are present at comparable frequencies in patients with PBC and controls have been challenged by the results of a recent study that antibody reactivity against *H. pylori* are more frequently present in patients with PBC than in controls (54% vs 31%).

Betaretroviruses: the viral triggers of PBC

Several studies have attempted to incriminate EBV and CMV in the pathogenesis of PBC but the data have been inconclusive. However, infection, with the mouse mammary tumour virus (MMTV) has been linked with PBC. Data from the group of Mason in Canada suggest that beta-retroviruses may indeed infect biliary epithelial cells, leading to increased PDC-E2 expression on the cell surface [16]. These authors were the first to show that anti-retroviral antibodies are frequently detectable in patients with PBC, and have also provided evidence for the appearance of viral particles in biliary epithelial cells of affected individuals. Mason has cloned a human betaretroviral sequence highly homologous to MMTV. As well, retroviral sequences were identified in a murine model of experimental cholangiopathy with features of PBC. Increased MMTV gag and env expression was found in the liver tissue of mice with immunological dysfunction. Also, titres of AMA correlated with anti-MMTV antibodies in these mice. All these findings have come from the same group, and external validation from two independent groups has failed to replicate these data. For example, Gershwin and co-workers have found MMTV less frequently in livers from PBC patients than in livers from patients with other chronic liver diseases.
Parasitic infections and PBC: the link with Toxoplasma gondii

Toxoplasmosis is caused by *Toxoplasma gondii*, a parasite within the genus Toxoplasma. Cats are the primary host of *T. gondii*. So far, this parasite has not been reported as a risk factor for PBC. However, a recent study has reported that antibodies against *Toxoplasma gondii* are more prevalent in patients with PBC compared to healthy controls (71% vs 40%, p<0.0001).

Table 1. Major findings involving infectious agents in the induction of primary biliary cirrhosis (PBC). Features vary amongst studies and therefore their strength of support differs amongst studies. None of them is conclusive of a decisive role of an infectious agent as a cause of PBC.

<table>
<thead>
<tr>
<th>Infectious Agent</th>
<th>Type of study</th>
<th>Finding</th>
<th>In support or against a causative link</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>E. coli</em></td>
<td>Clinical observation</td>
<td>Bacteriuria is more frequent in PBC than controls</td>
<td>In support</td>
</tr>
<tr>
<td></td>
<td>Clinical observation</td>
<td>Bacteriuria is equally prevalent in PBC patients and controls</td>
<td>Against</td>
</tr>
<tr>
<td></td>
<td>Epidemiological</td>
<td>History of urinary tract infection more frequently reported in patients than in controls</td>
<td>In support</td>
</tr>
<tr>
<td></td>
<td>Immunological</td>
<td>History of infection precedes disease</td>
<td>In support</td>
</tr>
<tr>
<td></td>
<td>Experimental animal model</td>
<td>Women with rUTI have PBC-specific AMA and ANA</td>
<td>In support</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Evidence of cross-reactive antibodies and T-lymphocytes</td>
<td>In support</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Infection induces AMA and causes PBC-like disease</td>
<td>In support</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Data have been reported in the form of an abstract, and other convincing animal models have not been developed</td>
<td>In support</td>
</tr>
<tr>
<td><em>N. amoraticivorans</em></td>
<td>Immunological</td>
<td>Presence of anti-microbial antibodies</td>
<td>In support</td>
</tr>
<tr>
<td></td>
<td>Microbiological</td>
<td>Evidence of microbial/self cross-reactive antibodies</td>
<td>In support</td>
</tr>
<tr>
<td></td>
<td>Experimental animal model</td>
<td>Positive faecal cultures</td>
<td>In support</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Infection induces AMA and causes PBC-like disease</td>
<td>In support</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Disease is transferable</td>
<td>In support</td>
</tr>
<tr>
<td><em>L. delbrueckii</em></td>
<td>Immunological</td>
<td>Evidence of cross-reactive antibodies</td>
<td>In support</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A woman develops PBC after lactobacilli vaccination</td>
<td>Against</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Antibodies are also found in controls</td>
<td></td>
</tr>
<tr>
<td><em>Betaretroviruses</em></td>
<td>Immunological</td>
<td>Anti-viral antibodies are present in PBC patients</td>
<td>In support</td>
</tr>
<tr>
<td></td>
<td>Virological</td>
<td>Cloning of MMTV from PBC patients</td>
<td>In support</td>
</tr>
<tr>
<td></td>
<td>Virological</td>
<td>Lack of molecular evidence</td>
<td>Against</td>
</tr>
<tr>
<td></td>
<td>Virological</td>
<td>Virus is less prevalent in liver of PBC than in other liver diseases</td>
<td>Against</td>
</tr>
<tr>
<td></td>
<td>Experimental Animal Model</td>
<td>Identification of retroviral sequences in a murine model of PBC</td>
<td>In support</td>
</tr>
<tr>
<td></td>
<td>Clinical</td>
<td>Inconclusive data regarding the efficacy of anti-viral treatment</td>
<td>Against</td>
</tr>
<tr>
<td>Infectious Agent</td>
<td>Type of study</td>
<td>Finding</td>
<td>In support or against a causative link</td>
</tr>
<tr>
<td>------------------</td>
<td>---------------</td>
<td>---------</td>
<td>--------------------------------------</td>
</tr>
<tr>
<td><em>M. gordonae</em></td>
<td>Microbiological</td>
<td>Molecular evidence of the mycobacterium is not limited to PBC</td>
<td>Against</td>
</tr>
<tr>
<td></td>
<td>Immunological</td>
<td>Presence of cross-reactive antibodies</td>
<td>In support</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anti-mycobacterial antibodies are specific for <em>M. gordonae</em></td>
<td>In support</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anti-mycobacterial antibodies are not specific for <em>M. gordonae</em></td>
<td>Against</td>
</tr>
<tr>
<td><em>Helicobacter pylori</em></td>
<td>Immunological</td>
<td>Lack of cross-reactive B- and T-cell responses</td>
<td>Against</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prevalence of anti-helicobacter antibodies is similar in patients and controls</td>
<td>Against</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prevalence is higher in patients than in controls</td>
<td>In support</td>
</tr>
<tr>
<td><em>Toxoplasma gondii</em></td>
<td>Immunological</td>
<td>Increased prevalence of antibodies in patients compared to controls</td>
<td>In support</td>
</tr>
<tr>
<td><em>Epstein-Barr Virus</em></td>
<td>Virological</td>
<td>Increased EBV DNA levels in patients than in controls</td>
<td>In support</td>
</tr>
<tr>
<td></td>
<td>Immunological</td>
<td>Prevalence of EBV early antigen-specific antibodies higher in PBC patients</td>
<td>In support</td>
</tr>
<tr>
<td><em>P. aeruginosa</em></td>
<td>Immunological</td>
<td>Evidence of T-cell cross-reactivity</td>
<td>In support</td>
</tr>
<tr>
<td><em>Human cytomegalovirus</em></td>
<td>Immunological</td>
<td>Lack of cross-reactive antibodies</td>
<td>Against</td>
</tr>
<tr>
<td><em>Haemophilus influenzae</em></td>
<td>Immunological</td>
<td>Lack of cross-reactive antibodies</td>
<td>Against</td>
</tr>
<tr>
<td><em>N. amoraticivorans</em></td>
<td>Immunological</td>
<td>Evidence of anti-microbial antibodies</td>
<td>In support</td>
</tr>
<tr>
<td></td>
<td>Microbiological</td>
<td>Evidence of microbial/self cross-reactive antibodies</td>
<td>In support</td>
</tr>
<tr>
<td></td>
<td>Experimental animal model</td>
<td>Positive faecal cultures</td>
<td>In support</td>
</tr>
<tr>
<td></td>
<td>Experimental animal model</td>
<td>Infection induces AMA and causes PBC-like disease</td>
<td>In support</td>
</tr>
<tr>
<td></td>
<td>Experimental animal model</td>
<td>Disease is transferable</td>
<td>In support</td>
</tr>
<tr>
<td><em>L. delbrueckii</em></td>
<td>Immunological</td>
<td>Evidence of cross-reactive antibodies</td>
<td>In support</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A woman develops PBC after lactobacilli vaccination</td>
<td>In support</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Antibodies are also found in controls</td>
<td>Against</td>
</tr>
<tr>
<td>Infections, Tumors and Autoimmunity</td>
<td>11</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| **Betaretroviruses** | **Immunological** | Anti-viral antibodies are present in PBC patients Cloning of MMTV from PBC patients Lack of molecular evidence Virus is less prevalent in liver of PBC than in other liver diseases Identification of retroviral sequences in a murine model of PBC Inconclusive data regarding the efficacy of anti-viral treatment | **In support** |
| | **Virological** | | | |
| | **Virological** | | | |
| | **Virological** | | | |
| | **Experimental Animal Model** | | | |
| | **Clinical** | | | |

| **M. gordonae** | **Microbiological** | Molecular evidence of the mycobacterium is not limited to PBC Presence of cross-reactive antibodies Anti-mycobacterial antibodies are specific for *M. gordonae* Anti-mycobacterial antibodies are not specific for *M. gordonae* | **Against** |
| | **Immunological** | | | |

| **Helicobacter pylori** | **Immunological** | Lack of cross-reactive B- and T-cell responses Prevalence of anti-helicobacter antibodies is similar in patients and controls Prevalence is higher in patients than in controls | **Against** |
| | | | | |

| **Toxoplasma gondii** | **Immunological** | Increased prevalence of antibodies in patients compared to controls | **In support** |
| | | | | |

| **Epstein-Barr Virus** | **Virological** | Increased EBV DNA levels in patients than in controls Prevalence of EBV early antigen-specific antibodies higher in PBC patients | **In support** |
| | | | | |

| **P. aeruginosa** | **Immunological** | Evidence of T-cell cross-reactivity | **In support** |
| | | | | |

| **Human cytomegalovirus** | **Immunological** | Lack of cross-reactive antibodies | **Against** |
| | | | | |

| **Haemophilus influenzae** | **Immunological** | Lack of cross-reactive antibodies | **Against** |
| | | | | |

### 3. Autoimmune Hepatitis

AIH is an autoimmune liver disease characterised by elevated transaminases, the presence of specific autoantibodies, raised IgG, and interface hepatitis on histology. AIH can be divided into AIH type 1 or type 2, which is largely based on distinct autoantibody profiles [17]. ANA and smooth muscle antibody (SMA) characterise type 1, with type 2 being characterised by liver kidney microsomal antigen type 1 (anti-LKM1) and anti-liver cytosol type 1 (anti-LC1) antibodies [17]. Immunosuppressive treatment is with prednisolone, with or without azathioprine.

The mechanisms underlying the development of AIH are not well defined, but there is some evidence to suggest a numerical and functional impairment of T regulatory cells may be involved. Genetic and environmental factors are also believed to be involved in the development of the disease, mostly viruses (Figure 1).
Hepatitis C Virus and AIH

HCV has been investigated as a potential inducer of AIH, which has been based on the observation that AIH-related autoantibodies are frequently present in chronically infected patients with HCV. In fact, ANA, SMA, as well as anti-LKM1 antibodies can be found in up to 40% of patients with HCV infection. Several research groups, including our own, have shown that HCV and cytochrome P450 2D6, the autoantigen of anti-LKM1 antibodies, are targets of cross-reactive responses and that molecular mimicry operates at the B and T cell levels [18, 19]. We have also demonstrated that molecular mimicry and immunological cross-reactivity involving HCV, and AIH-1 related smooth muscle, nuclear autoantigens may explain the presence of AIH-related autoantibodies during viral infection [19].

As more than 350 million people world-wide are infected with HCV, it could be expected that more cases with AIH could be induced as a result of viral infection with this hepatotropic virus but this does not appear to be the case. Thus, as it stands, the current evidence linking HCV with AIH is not strong.

Other Hepatotropic Viruses: Hepatitis A and B

Several case reports have noted the development of AIH after HAV infection [20]. As well, the histological appearance of acute HAV induced liver damage and AIH may be indistinguishable. Patients infected with HAV and HBV appear to be seropositive for AIH-related autoantibodies such as ANA, SMA and anti-asialoglycoprotein receptor antibodies. This suggested that HAV/HBV infection might trigger a humoral immune response to liver antigens, leading to the subsequent induction of the liver disease. A group of researchers prospectively followed a cohort of relatives of AIH patients, and obtained regular serum samples for the detection of serological markers of AIH. In three of these cases, the relative developed AIH type 1 (with anti-ASGPR positivity) following infection with HAV. It should also be noted that AIH has been reported following HAV vaccinations (see Vaccination section below). Despite these reports, larger molecular studies are needed to determine whether a link between hepatotropic viruses and AIH exist.

Epstein-Barr Virus: Case Reports in AIH

Several cases report the development of AIH following EBV infection [20]. A group of investigators followed relatives of AIH patients, and regularly assessed them for evidence of AIH [21]. Two individuals developed AIH following EBV infection and infectious mononucleosis [21].

It should be noted that EBV infection of the liver might resemble AIH, which should be differentiated histologically. For example, one report describes the case of fatal chronic active EBV infection mimicking AIH [20].

Currently, no large studies have been conducted investigating the role of EBV in the development of AIH. Unlike HCV, the molecular mechanisms that may be involved in the development of AIH following EBV infection (including molecular mimicry and cross reactivity) have not been explored. It currently appears that EBV may induce AIH in individual cases, but there is no conclusive evidence linking EBV with AIH. As well, the prevalence of EBV would infer a higher rate of AIH (if a link was present), and this is not the case.

Herpes Simplex Virus 1

As noted previously in the case of HCV, a study indicated that the immunodominant regions of CYP2D6 share homologous regions with HCV and HSV-1, and suggested that HCV-negative AIH type 2 cases may be related to HSV-1 [19]. We have shown that the ICP4 protein from HSV-1 shares antigenic determinants
with the HCV RNA polymerase and that the mimicking sequences are targets of cross-reactive responses. However, rates of anti-HSV-1 antibodies are comparable between patients with AIH and demographically matched controls [19].

**Vaccinations preceding AIH**

Vaccinations to prevent from infectious agents have been used as models to study the induction of autoimmunity triggered by foreign pathogens. Case reports comprise most of the evidence linking vaccinations and AIH [20]. One case report describes a case of AIH developing one week after vaccinations for typhoid, hepatitis A, diphtheria/tetanus, oral polio, mumps, measles and rubella (reviewed in [20]). Although liver biopsy and clinical data was suggestive of AIH, it is not known if any autoantibodies were present. That patient responded well to immunosuppressive therapy. Another case reports of a 31-year-old female who presented with a ten day history of nausea, vomiting, fever, and dark urine, which began eleven days after receiving a vaccination for hepatitis A and yellow fever (reviewed in [20]). She was diagnosed with AIH, and responded well to steroid therapy. It should be noted that this patient was serologically negative for autoantibodies associated with AIH, and also notes the development of symptoms whilst abroad in Nigeria. Apart from case reports, there is no direct evidence or larger studies linking vaccination to AIH. Further investigations into liver disease following vaccinations are warranted, as vaccinations have been linked with other autoimmune conditions.

![Figure 1](image_url). Viruses involved in the pathogenesis of autoimmune hepatitis (AIH) type 1 and type 2. Arrows indicate links between a virus and a specific type of AIH. HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus; HDV, hepatitis D virus; HEV, hepatitis E virus; EBV, Epstein-Barr Virus; CMV, cytomegalovirus; HSV-1, human herpes virus-1; ADV, adenovirus; VZV, varicella zoster virus.
4. **Primary sclerosing cholangitis**

PSC is a chronic progressive cholestatic disease, characterized by immune-mediated destruction of the biliary epithelial cells leading to fibrosis and biliary cirrhosis. Unlike most autoimmune conditions, PSC has a higher male predominance. PSC is largely diagnosed based on endoscopic cholangiography and/or magnetic resonance imaging, as well as biochemical indices of cholestasis and disease-related perinuclear anti-neutrophilic antibodies (p-ANCA) [2]. Treatment of PSC includes administration of ursodeoxycholic acid, although curative treatment consists of liver transplantation. Both PBC and PSC are autoimmune disorders characterized by the immune-destruction of the biliary epithelial cells, but the diseases are quite distinct and there are no patients with concomitant overlapping features of PBC and PSC. In fact, PBC can co-exist with AIH, and the same appears to be the case for AIH and PSC.

The link between PSC and infectious triggers is far from clear.

**Epstein-Barr Virus and Primary Sclerosing Cholangitis**

To date, the only evidence of an infectious trigger is PSC is in regards to EBV [22], which is related to ulcerative colitis (UC), an inflammatory bowel disease which is often concurrent with PSC. Some studies have found an increased number of EBV-infected B lymphocytes in intestinal mucosal samples from patients with ulcerative colitis compared to healthy controls [22]. However, it is unclear as to how many of those patients also had concomitant PSC. To date, there does not appear to be strong or direct evidence linking EBV and PSC.

5. **Conclusion**

Evidence linking autoimmune liver diseases to infectious agents varies from one condition to the next. *E. coli* appears to be strongly linked to PBC development, based on epidemiological as well as experimental and molecular studies. It also appears likely that other infectious agents may be involved. The evidence is not as strong in AIH and PSC. Although several viruses (namely the hepadnaviridae and HSV) have been implicated in the form of case reports, stronger molecular evidence is needed to make definitive conclusions regarding infection and AIH. So far, very little evidence exists in regards to infection and PSC.

**References**

Infections, Tumors and Autoimmunity


GP2 – The link between innate and acquired immune system in the intestine

Dirk Roggenbuck¹,², Dirk Reinhold³, Dimitrios P. Bogdanos⁴, Karsten Conrad⁵

1) Faculty of Natural Sciences, Brandenburg Technical University Cottbus-Senftenberg, Senftenberg, Germany
2) GA Generic Assays GmbH, Dahlewitz, Germany
3) Institute of Molecular and Clinical Immunology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany
4) Institute of Liver Studies, Division of Transplantation Immunology and Mucosal Biology, King’s College London School of Medicine at King’s College Hospital, UK
5) Institute of Immunology, Technical University Dresden, Dresden, Germany

E-mail: dirk.roggenbuck@hs-lausitz.de

Keywords

Inflammatory bowel disease, Crohn’s disease, Glycoprotein 2, Innate and acquired immunity

Abbreviations

CD, Crohn’s disease; GP2, glycoprotein 2; IBD, inflammatory bowel disease; M cell, microfold cell; PAB, pancreatic autoantibodies; PP, Peyer’s patches; SREC-I, scavenger receptor expressed on endothelial cells I; THP, Tamm-Horsfall protein; UC, ulcerative colitis
Autoantibodies against glycoprotein 2 in inflammatory bowel diseases

Glycoprotein 2 has been identified as a major autoantigenic target of pancreatic antibodies (PAB) found in patients with Crohn’s disease (CD).[1-3] The loss of tolerance in inflammatory bowel diseases (IBD) has been reported first in the late 1970s by demonstrating the occurrence of autoimmunity in ulcerative colitis (UC), the other main IBD along with CD.[4] First reports on humoral autoimmunity in CD can be traced back to the late 1980s.[5] Ever since, the pathophysiology of both IBDs and the respective role of immune processes in particular autoimmunity remains poorly understood. The incidence of IBD is steadily increasing in developed and developing countries, which amounts approximately up to 37.1 per 100,000 individuals each year in Europe currently.[6] In the United States alone, IBD is one of the five most prevalent gastrointestinal disorders, accounting for more than 700,000 physician visits and 100,000 hospitalizations with an overall healthcare cost of more than $1.7 billion (CDC data). From a prognostic point of view, up to 75% of patients suffering from CD and 25% of those with UC will require surgery. There is a common belief that pediatric entities of IBD are distinct diseases in comparison with the ones seen in adults. Apart from common susceptibility loci, genome-wide association studies (GWAS) have identified new loci associated with early onset of IBD in children which were not found in adults.

Apart from autoimmunity, genetic predisposition and environmental factors play a pivotal role in the pathophysiology of IBD. By means of GWAS, IBD5 locus (5q31-33 region) has been demonstrated to be strongly associated with UC, whereas the NOD2 (16q12) and major histocompatibility complex (MHC) (6p21) locus appears to be linked to CD.[7] The inflammation observed in CD which penetrates all layers of the bowel wall and adventitia in contrast to the one seen in UC can manifest throughout the whole digestive tract. Tissue lesions such as fissures, abscesses, strictures, and fistulas can develop in the course of CD and the incidence of carcinoma is particularly elevated in patients with Crohn’s colitis after extended disease.

The “western” or “westernized” diet is obviously one of the most critical environmental components to be taken into account in terms of the pathophysiology of IBD. Whereas an increased intake of refined carbohydrates, fatty acids, and proteins have been associated with CD and/or UC, the consumption of dietary fiber in the form of vegetables and fruits seems to be correlated with a reduced risk of IBD development. The eating habit may contribute to the triggering of IBDs by a direct effect of dietary antigens, alterations in gene expression, or an impact on the composition of the enteric flora. In this context, gastrointestinal permeability appears to play a critical role.

Notably, autoimmunity is believed to play a major role in IBD inflammation leading to overt disease. In CD, approximately 30% of patients and less than 8% of patients with UC develop loss of tolerance to exocrine pancreas.[8] As a matter of fact, GP2 the major target of PAB is the most abundant membrane protein in pancreatic acinar cells and is not found in endocrine pancreas tissue. The previously unaddressed contradiction of pancreatic autoreactivity and intestinal inflammation in CD was elucidated by demonstrating the expression of GP2 at the site of CD inflammation.[1;9] Notably, GP2 has been found on the surface of microfold (M) cells of intestinal Peyer’s patches (PP),[10] which are believed to represent the origin of CD inflammation.[11] Apparently, GP2 seems to support the transcytosis of FimH positive bacteria by M cells through the PP to the underlying gut associated lymphoid tissue. The binding of a subset of commensal and pathogenic enterobacteria, including Escherichia coli and Salmonella enteric serovar Typhimurium (Salmonella typhimurium) has been demonstrated to be mediated by FimH, a component of type I pili on the bacterial outer membrane.
The development of immunoassays for the detection of antibodies to GP2 has paved the way to investigate the association of such antibodies with the clinical phenotype in CD.[12-16] Thus, patients suffering from CD with ileocolonic location revealed a significantly higher prevalence of anti-GP2.[17-19] Even more interestingly, CD patients with stricturing behaviour and perianal disease demonstrated a higher prevalence of anti-GP2. These observations support the assumption that the loss of tolerance to GP2 is correlated with the phenotype of patients with CD. Therefore, it is tempting to speculate about an association of autoreactivity to GP2 with fibrostenosis in CD and anti-GP2 antibodies could be an interesting candidate for a fibrostenosis marker in CD. This may provide the basis for further stratification of CD patients with regard to the type and outcome of inflammation.[20-22]

**GP2 and GP2 autoantibodies in the pathogenesis of Crohn's disease**

Mucosal inflammation in CD appears to be brought about by dysregulation of the immune system due to an imbalance between tolerance to commensal microbiota or food-derived antigens and immunity to pathogens.[23] In this context it is quite remarkable that the expression of GP2 is elevated in the inflamed tissue of patients with CD compared to patients with UC.[1] This hints to a possible involvement of GP2 in the immune processes leading to inflammation apart from its antimicrobial receptor function. Interestingly, the homolog of GP2 in the urinary tract, the Tamm-Horsfall protein (THP), has been reported to be a regulatory factor of innate and adaptive immunity.[24] Thus, it was not surprising, that GP2 apparently executes a similar effect like THP in modulating innate and adaptive immunity in the intestine.[25] Recently, GP2 has been identified as a binding partner of the scavenger receptor expressed on endothelial cells I (SREC-I), which is also located on dendritic cells.[26] Monocyte-derived dendritic cells bear SREC-I and can interact with GP2 and internalize GP2 or complexes thereof. It is well accepted that innate and adaptive immune responses in the intestinal mucosa are linked by dendritic cells. Such dendritic cells may induce tolerance by releasing the antiinflammatory cytokine IL10 or promote inflammation through the shedding of IL12. Genetic polymorphisms of IL10 and IL12 are associated with the risk to develop IBDs underscoring the assumption adaptive immunity plays a critical role in the pathophysiology of IBD. It could be demonstrated that GP2 distinctly modulates cytokine secretion. Using organ culture assays, GP2 reduced pro-inflammatory CXCL8 secretion in freshly resected mucosal specimens and up-regulated TGFβ1.[25] These data suggests an anti-inflammatory role of GP2 in the mucosal immune system.

Noteworthy, the expression of GP2 is up-regulated on activated human T cells and can be modulated by pharmaceutical TNFα inhibitors. GP2 significantly reduces proliferation, apoptosis, and activation of human intestinal epithelial cells as well mucosal and peripheral T cells.[25] Remarkably, the immunosuppressive effects of GP2 were shown to be mediated by regulatory T cells. It has been shown that intraepithelial lymphocytes mediate the primary response to foreign antigens, but can be also autoreactive. Thus, GP2 seems to partake in keeping the balance of the intestinal immune system fulfilling the enormous task of differentiating between pathogenic and commensal microbiota.[13]

Given the recently discovered immunomodulating role of GP2 in innate and acquired intestinal immunity, this association can shed further light on the pathophysiology of IBD which is a complex interaction of susceptibility genes, environmental factors, and innate as well as adaptive immunity.

**Competing interests**

Dirk Roggenbuck is a shareholder of GA Generic Assays GmbH and Medipan GmbH. Both companies are diagnostic manufacturers. All other authors declare that they have no competing financial interests.
Figure 1. Glycoprotein 2 (GP2) in the pathophysiology of Crohn’s disease
GP2 located on the surface of M cells (M) of the follicle-associated epithelium (FAE) can interact with FimH positive bacteria and present these potential pathogens to the underlying mucosa associated lymphoid tissue (MALT) by transcytosis. After having presented the microbial antigens to dendritic cells, T cells (T) will be activated by these potent antigen-presenting cells and B cells (B) will be transformed into plasma cells (P) producing antimicrobial antibodies.
Elevated expression of GP2 seen in CD can interfere with GP2’s interaction with dendritic calls and reduce proliferation and apoptosis of T cells.
The loss of tolerance to GP2 observed in CD may lead to the production of anti-GP2 antibodies. These autoantibodies may in turn neutralize the suppressive effect of GP2 in the MALT.

References

(3) Roggenbuck D, Bogdanos D, Conrad K. Loss of tolerance to one or two major targets in Crohn’s disease or just cross-reactivity? J Crohns Colitis 2013;7:e273-e274.


